Roivant Sciences Ltd.
Roivant Sciences (ROIV) received a $950 million settlement from Moderna, improving its cash position. The company is advancing its inflammation and immunology pipeline, with brepocitinib as a key catalyst. Roivant projects $2.0b revenue and $339.3m earnings by 2029, assuming significant growth.
Epperly Melissa B, sold 17,750 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.10 ($36.08–$36.57, $0.64M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ROIV (Roivant Sciences Ltd.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent ROIV coverage spans financial news, insider activity and technology.
In the last 30 days, ROIV insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($9.2M). The most active reporter was Epperly Melissa B, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The settlement boosts cash reserves, reducing financing needs and supporting late‑stage trial funding.
The insider sale may create modest selling pressure on ROIV.
Positive settlement news likely supports upside for ROIV.
Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.
The insider sale may signal modest selling pressure.
AlphAI scores every news story that mentions ROIV with an AI model for sentiment and relevance, and aggregates insider trades from Roivant Sciences Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Roivant Sciences (ROIV) received a $950 million settlement from Moderna, improving its cash position. The company is advancing its inflammation and immunology pipeline, with brepocitinib as a key catalyst. Roivant projects $2.0b revenue and $339.3m earnings by 2029, assuming significant growth.
2 min readEpperly Melissa B, sold 17,750 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.10 ($36.08–$36.57, $0.64M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readRoivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.
3 min readRoivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.
3 min readRoivant Sciences Ltd. (ROIV) withheld 46,879 shares for tax purposes, according to an SEC Form 4 filing. The transaction was reported by Mayukh Sukhatme, President & CIO, and occurred on 09/30/2026 at a price of $36.57 per share.
1 min readVenker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $36.62 ($7.32M total) on 2026-09-30 under a Rule 10b5-1 trading plan.
1 min readRoivant Sciences Ltd. officer Eric Venker plans to sell 200,000 common shares worth $7.32M, according to a filing. The sale is scheduled for September 30, 2026, under a Rule 10b5-1 trading plan adopted in March 2025.
1 min readRoivant Sciences (NASDAQ:ROIV) anticipates updates on IMVT-1402, including Phase II data for rheumatoid arthritis and lupus, and a 2027 catalyst for Graves' disease. The company is also reassessing indications for mosliciguat post-Phase II results. Roivant aims to grow its pipeline but may consider asset sales for attractive offers.
2 min readRoivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.
3 min readRoivant (ROIV) reported mixed results from a study of IMVT-1402 for cutaneous lupus. The drug showed positive trends but missed the primary endpoint. The company will not advance the treatment for this indication but will continue development for other autoimmune diseases. ROIV stock is down 0.52% at $38.02.
2 min read
